Your browser doesn't support javascript.
loading
Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes' army.
García-Muñoz, Ricardo; Nájera, María-Josefa; Feliu, Jesús; Antón-Remírez, Judith; Ramalle-Gómara, Enrique; Marín-Gorricho, Raquel; Peralta, Raisa; Gutiérrez-Gamarra, Elena; Nuñez-Rodriguez, Jessica; Zafra-Morales, Ricardo; Aguinaga, Lorea; Nebot-Villacampa, María-Jose; Hernandez-Pérez, Prisma-Monserrat; Farfán-Quiroga, Giovanna; Panizo, Carlos; Domínguez-Garrido, Elena.
Afiliação
  • García-Muñoz R; Department of Hematology, San Pedro Hospital, 26006 Logroño, La Rioja, Spain.
  • Nájera MJ; Department of Hematology, San Pedro Hospital, 26006 Logroño, La Rioja, Spain.
  • Feliu J; Department of Hematology, San Pedro Hospital, 26006 Logroño, La Rioja, Spain.
  • Antón-Remírez J; Department of Physical Medicine & Rehabilitation, Navarra Hospital Complex, Pamplona, Spain.
  • Ramalle-Gómara E; Department of Epidemiology, La Rioja Regional Authority, Logroño, La Rioja, Spain.
  • Marín-Gorricho R; Department of Pharmacy, San Pedro Hospital, Logroño, La Rioja, Spain.
  • Peralta R; Department of Hematology, San Pedro Hospital, 26006 Logroño, La Rioja, Spain.
  • Gutiérrez-Gamarra E; Department of Hematology, Poniente Hospital, Almería, Andalucía, Spain.
  • Nuñez-Rodriguez J; Department of Pharmacy, San Pedro Hospital, Logroño, La Rioja, Spain.
  • Zafra-Morales R; Department of Pharmacy, San Pedro Hospital, Logroño, La Rioja, Spain.
  • Aguinaga L; Department of Hematology, Centre Hospitalier Universitaire (CHU), Bordeaux, France.
  • Nebot-Villacampa MJ; Department of Pharmacy, San Pedro Hospital, Logroño, La Rioja, Spain.
  • Hernandez-Pérez PM; Department of Hematology, San Pedro Hospital, 26006 Logroño, La Rioja, Spain.
  • Farfán-Quiroga G; Department of Hematology, San Pedro Hospital, 26006 Logroño, La Rioja, Spain.
  • Panizo C; Hematology Department, University Clinic of Navarra, Pamplona, Navarra, Spain. Lymphoproliferative Group, Navarran Institute for Health Research (IDISNA), Pamplona, Navarra, Spain.
  • Domínguez-Garrido E; Molecular Diagnostic Unit, Rioja Health Foundation, Logroño, La Rioja, Spain.
Future Sci OA ; 5(10): FSO425, 2019 Nov 26.
Article em En | MEDLINE | ID: mdl-31827894
ABSTRACT

AIM:

To analyze the effects of subcutaneous or intravenous rituximab + lymphokine-activated killer cells, obinutuzumab or ibrutinib on natural killer (NK) cell levels in chronic lymphocytic leukemia and follicular lymphoma patients. PATIENTS &

METHODS:

The distribution of peripheral blood NK cells of 31 patients was analyzed by flow cytometry.

RESULTS:

We detected a decrease of NK cells in peripheral blood below normal range after obinutuzumab treatment. During maintenance treatment with subcutaneous rituximab, an NK cell reduction was less pronounced than after intravenous rituximab treatment, despite lymphokine-activated killer cell infusions.

CONCLUSION:

After one dose of obinutuzumab, each NK cell in peripheral blood destroys 25 leukemic cells.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article